Literature DB >> 15979035

Molecular studies in Portuguese patients with Smith-Lemli-Opitz syndrome and report of three new mutations in DHCR7.

M L Cardoso1, A Balreira, E Martins, L Nunes, A Cabral, M Marques, M Reis Lima, J S Marques, A Medeira, I Cordeiro, S Pedro, M C Mota, C Dionisi-Vici, F M Santorelli, C Jakobs, P T Clayton, L Vilarinho.   

Abstract

Smith-Lemli-Opitz syndrome (SLO) is an autosomal recessive disorder characterised by craniofacial dysmorphism, mental retardation, multiple congenital anomalies, and increased levels of 7-dehydrocholesterol (7-DHC) in body tissues and fluids. SLO is caused by mutations in the DHCR7 gene which encodes 7-dehydrocholesterol reductase, the last enzyme of cholesterol biosynthesis pathway. In our investigation, we screened 682 dysmorphic/mentally retarded Portuguese patients for abnormal levels of 7-DHC in blood by UV spectrometry. We identified six unrelated patients with SLO (0.87% of total). Mutational analysis of the DHCR7 gene led to the identification of seven distinct mutations, three of which are new (F174S, H301R, and Q98X). The common IVS8-1G > C and T93M variants together with the H301R accounted for 70% of the all SLO alleles in our population. Our findings contribute to the variegate array of pathological changes in the DHCR7 gene among different European populations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979035     DOI: 10.1016/j.ymgme.2005.02.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  3 in total

Review 1.  Recent insights into the Smith-Lemli-Opitz syndrome.

Authors:  H Yu; S B Patel
Journal:  Clin Genet       Date:  2005-11       Impact factor: 4.438

2.  The p.Phe174Ser mutation is associated with mild forms of Smith Lemli Opitz Syndrome.

Authors:  Arianna Tucci; Luisa Ronzoni; Carlo Arduino; Paola Salmin; Susanna Esposito; Donatella Milani
Journal:  BMC Med Genet       Date:  2016-03-11       Impact factor: 2.103

Review 3.  Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.

Authors:  M R Boland; N P Tatonetti
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.